The moderate to severe atopic dermatitis market is experiencing significant growth with 45+ companies developing over 50 pipeline therapies, driven by rising global prevalence and increased awareness of the condition.
Apogee Therapeutics will announce interim results from its Phase 1 healthy volunteer trial of APG990, advancing their portfolio of novel biologics for inflammatory and immunology conditions.